• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Enzyme alterable alkylating agents. 8. Clinical trials with intra-arterial infusion of an alkylating agent with a half-life of 0.2 second.

作者信息

Goodman L E, Ulfohn A, Kramer S P, Cendana E H, Flores A B, Bakal D, Abrams S J, Hirschfeld R L, Calle S, Williamson C E, Sass S, Witten B, Seligman A M

出版信息

Ann Surg. 1965 Oct;162(4):663-89. doi: 10.1097/00000658-196510000-00011.

DOI:10.1097/00000658-196510000-00011
PMID:5319397
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1476944/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1be/1476944/bccde71cdee1/annsurg00460-0148-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1be/1476944/77c829c0f976/annsurg00460-0144-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1be/1476944/6ee1ac1f48d6/annsurg00460-0145-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1be/1476944/bccde71cdee1/annsurg00460-0148-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1be/1476944/77c829c0f976/annsurg00460-0144-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1be/1476944/6ee1ac1f48d6/annsurg00460-0145-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1be/1476944/bccde71cdee1/annsurg00460-0148-a.jpg

相似文献

1
Enzyme alterable alkylating agents. 8. Clinical trials with intra-arterial infusion of an alkylating agent with a half-life of 0.2 second.酶可变烷化剂。8. 关于动脉内输注半衰期为0.2秒的烷化剂的临床试验。
Ann Surg. 1965 Oct;162(4):663-89. doi: 10.1097/00000658-196510000-00011.
2
The clinical trial of an alkylating agent with a short half-life designed for intra-arterial chemotherapy.一种半衰期短、设计用于动脉内化疗的烷化剂的临床试验。
Cancer. 1971 Feb;27(2):369-73. doi: 10.1002/1097-0142(197102)27:2<369::aid-cncr2820270220>3.0.co;2-5.
3
Initial clinical trial of dibromodulcitol (NSC-104800) in patients with advanced cancer.二溴卫矛醇（NSC - 104800）用于晚期癌症患者的初步临床试验。
Cancer Chemother Rep. 1971 Dec;55(5):583-9.
4
Clinical experiences with dibromodulcitol (NSC-104800) in solid tumors.二溴卫矛醇（NSC - 104800）治疗实体瘤的临床经验
Cancer Chemother Rep. 1971 Dec;55(5):567-73.
5
[Indications and contraindications to intra-arterial infusion of chemical preparations in stomach cancer].[胃癌化学制剂动脉内灌注的适应证与禁忌证]
Klin Khir (1962). 1969 Oct;10:78-9.
6
Intra-arterial infusion of the chemotherapeutic agents methotrexate and "epodyl" in patients with advanced localized carinomata recurrent after radiotherapy.对放疗后复发的晚期局限性癌患者进行动脉内输注化疗药物甲氨蝶呤和“依托泊苷”。
Aust N Z J Surg. 1970 May;39(4):371-9. doi: 10.1111/j.1445-2197.1970.tb05376.x.
7
Enzyme alterable alkylating agents. XI. Clinical trials of an esterase-susceptible water-soluble agent (S-73) for regional chemotherapy.酶可改变的烷化剂。十一、一种酯酶敏感的水溶性药物（S-73）用于区域化疗的临床试验。
J Surg Res. 1971 May;11(5):217-23. doi: 10.1016/0022-4804(71)90024-2.
8
Protective hypothermia for cancer chemotherapy.癌症化疗的保护性低温疗法。
Br J Anaesth. 1967 Oct;39(10):806-12. doi: 10.1093/bja/39.10.806.
9
Hypothermia and cancer chemotherapy.体温过低与癌症化疗
Anesth Analg. 1969 Jan-Feb;48(1):92-8.
10
Enzyme alterable alkylating agents: a new approach to regional chemotherapy by intra-arterial infusion of new short-lived alkylating agents.酶可变烷化剂：通过动脉内输注新型短效烷化剂进行区域化疗的新方法。
Ann Surg. 1962 Sep;156(3):429-41. doi: 10.1097/00000658-196209000-00010.

本文引用的文献

1
Development of New Methods for the Histochemical Demonstration of Hydrolytic Intracellular Enzymes in a Program of Cancer Research.癌症研究项目中用于细胞内水解酶组织化学显示的新方法的开发
Ann Surg. 1949 Sep;130(3):333-41.
2
Intra-arterial catheterization of viscera in man.人体内脏的动脉内插管术。
Am J Roentgenol Radium Ther. 1951 Oct;66(4):555-68.
3
Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report.分次动脉内癌症；盐酸甲基双胺化疗；初步报告。
Ann Surg. 1950 Oct;132(4):811-32. doi: 10.1097/00000658-195010000-00018.
4
ENZYME-ALTERABLE ALKYLATING AGENTS. VII. THE DESIGN OF SHORT-LIVED MUSTARDS.酶可变烷化剂。VII. 短效芥子气的设计。
J Med Chem. 1965 Jan;8:14-7. doi: 10.1021/jm00325a003.
5
CLINICAL EXPERIENCE WITH N-HEXAMETHYLENE N'N'-DIETHYLENE THIOPHOSPHORAMIDE (KC-33), A NEW AGENT FOR BREAST AND OVARIAN CARCINOMA.N-亚甲基-N'N'-二乙烯基硫代磷酰胺（KC-33）治疗乳腺癌和卵巢癌的临床经验，一种治疗乳腺癌和卵巢癌的新型药物。
Cancer. 1965 Mar;18:307-12. doi: 10.1002/1097-0142(196503)18:3<307::aid-cncr2820180307>3.0.co;2-n.
6
DIMETHYL SULFOXIDE (DMSO): A NEW CONCEPT IN PHARMACOTHERAPY.二甲基亚砜（DMSO）：药物治疗的新概念。
Curr Ther Res Clin Exp. 1964 Feb;6:134-5.
7
ENZYME ALTERABLE ALKYLATING AGENTS. V. DESIGN OF SULFUR MUSTARDS WITH VARYING DEGREES OF HYDROLYTIC STABILITY IN A SEARCH FOR SHORT BIOLOGICAL HALF-LIFE AGENTS.酶可改变的烷基化剂。V. 设计具有不同程度水解稳定性的硫芥以寻找短生物半衰期的试剂。
J Natl Cancer Inst. 1963 Aug;31:273-96.
8
New short half-life alkylating agents for intra-arterial regional chemotherapy.用于动脉内区域化疗的新型短半衰期烷化剂。
Cancer Chemother Rep. 1962 Feb;16:515-6.
9
Enzyme-alterable alkylating agents. IV. Treatment of cancer in children with repetitive massive doses of S-46, protecting the extremity marrow by tourniquets.酶可改变的烷化剂。IV. 用重复大剂量S-46治疗儿童癌症，通过止血带保护肢体骨髓。
Cancer. 1963 Jun;16:727-36. doi: 10.1002/1097-0142(196306)16:6<727::aid-cncr2820160607>3.0.co;2-2.
10
Continuous arterial infusion of methotrexate with intermittent, intramuscular citrovorum factor therapy in head and neck cancer.
Trans Pac Coast Otoophthalmol Soc Annu Meet. 1961;42:29-42.